Jessica Fye
Stock Analyst at JP Morgan
(4.37)
# 407
Out of 4,996 analysts
205
Total ratings
60.94%
Success rate
13.84%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $53 → $52 | $45.91 | +13.27% | 6 | Sep 24, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $116 → $121 | $98.08 | +23.37% | 13 | Sep 22, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $53 → $77 | $72.76 | +5.83% | 4 | Sep 12, 2025 | |
| ALKS Alkermes | Maintains: Neutral | $34 → $35 | $27.89 | +25.49% | 7 | Sep 9, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $77 → $78 | $33.37 | +133.74% | 3 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $48 → $49 | $64.09 | -23.55% | 6 | Aug 25, 2025 | |
| INCY Incyte | Maintains: Neutral | $67 → $73 | $82.70 | -11.73% | 8 | Aug 22, 2025 | |
| INSM Insmed | Maintains: Overweight | $111 → $135 | $137.03 | -1.48% | 9 | Aug 20, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $254 → $260 | $191.99 | +35.42% | 15 | Aug 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $60 → $63 | $73.75 | -14.58% | 14 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $348 → $475 | $446.40 | +6.41% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $321 → $345 | $326.06 | +5.81% | 3 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $515 → $517 | $385.74 | +34.03% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $113 | $53.85 | +109.84% | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $432.66 | -23.73% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $33 → $26 | $24.49 | +6.17% | 13 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $7.63 | +70.38% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $34.02 | +46.97% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $12.89 | +117.22% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $127.00 | +64.57% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $13.95 | +72.04% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $17.51 | +71.33% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $24.14 | -46.15% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $58.50 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.91 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.65 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $16.00 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.44 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.59 | +1,283.65% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.40 | +400.00% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.57 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.55 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.90 | - | 1 | Feb 8, 2018 |
Crinetics Pharmaceuticals
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $45.91
Upside: +13.27%
BioNTech SE
Sep 22, 2025
Maintains: Neutral
Price Target: $116 → $121
Current: $98.08
Upside: +23.37%
Mirum Pharmaceuticals
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $72.76
Upside: +5.83%
Alkermes
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $27.89
Upside: +25.49%
Legend Biotech
Aug 25, 2025
Maintains: Overweight
Price Target: $77 → $78
Current: $33.37
Upside: +133.74%
Ionis Pharmaceuticals
Aug 25, 2025
Maintains: Neutral
Price Target: $48 → $49
Current: $64.09
Upside: -23.55%
Incyte
Aug 22, 2025
Maintains: Neutral
Price Target: $67 → $73
Current: $82.70
Upside: -11.73%
Insmed
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $137.03
Upside: -1.48%
Ascendis Pharma
Aug 19, 2025
Maintains: Overweight
Price Target: $254 → $260
Current: $191.99
Upside: +35.42%
Halozyme Therapeutics
Aug 7, 2025
Maintains: Neutral
Price Target: $60 → $63
Current: $73.75
Upside: -14.58%
Aug 6, 2025
Maintains: Overweight
Price Target: $348 → $475
Current: $446.40
Upside: +6.41%
Jul 17, 2025
Maintains: Overweight
Price Target: $321 → $345
Current: $326.06
Upside: +5.81%
Jul 14, 2025
Maintains: Overweight
Price Target: $515 → $517
Current: $385.74
Upside: +34.03%
Jul 14, 2025
Maintains: Overweight
Price Target: $108 → $113
Current: $53.85
Upside: +109.84%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $432.66
Upside: -23.73%
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $24.49
Upside: +6.17%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $7.63
Upside: +70.38%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $34.02
Upside: +46.97%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $12.89
Upside: +117.22%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $127.00
Upside: +64.57%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $13.95
Upside: +72.04%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $17.51
Upside: +71.33%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $24.14
Upside: -46.15%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $58.50
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.91
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.65
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $16.00
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.44
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.59
Upside: +1,283.65%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.40
Upside: +400.00%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.57
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.55
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $7.90
Upside: -